Related Experiment Video
Updated: Jul 9, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Dynamic Versus Static Cardiac Biomarker Assessment for Prognostic Stratification After Percutaneous Coronary
Nabila N Anika1,2, Mohamed K Said3, Hamza Al Balushi4
1General Surgery, University of South Florida Health, Florida, USA.
Insights
Serial cardiac biomarker assessment, particularly NT-proBNP, may improve risk prediction in percutaneous coronary intervention (PCI) patients compared to single measurements. Dynamic evaluation offers insights into ischemic burden and reperfusion dynamics.
Area of Science:
- Cardiology
- Biomarker Research
- Interventional Cardiology
Background:
- Cardiac biomarkers are crucial for risk stratification in percutaneous coronary intervention (PCI).
- Optimal timing and mode of cardiac biomarker assessment post-PCI remain unclear.
- Current guidelines lack definitive recommendations on serial vs. single biomarker measurements.
Purpose of the Study:
- To systematically review and evaluate the prognostic significance of serial, delta, and peak cardiac biomarker measurements versus single baseline measurements in PCI patients.
- To compare the predictive value of different cardiac biomarkers (troponin, NT-proBNP, CK-MB) and assessment strategies.
- To identify optimal biomarker assessment strategies for improved risk stratification in PCI.
Main Methods:
- Systematic literature review of PubMed/MEDLINE, Scopus, and Web of Science.
- Inclusion of nine cohort studies across diverse PCI settings (elective, primary, CTO).
- Assessment of various biomarkers (high-sensitivity troponin, conventional troponin, NT-proBNP, CK-MB) using baseline, peak, serial, and delta strategies.
Main Results:
- Baseline troponin levels consistently predict outcomes post-PCI.
- Post-procedural troponin elevations show variable prognostic value, dependent on thresholds.
- Serial assessment of N-terminal pro-B-type natriuretic peptide (NT-proBNP) enhances prognostic discrimination and reflects pathophysiologic processes.
Conclusions:
- Dynamic biomarker assessment, especially NT-proBNP, may offer incremental prognostic value over static measurements in PCI.
- Clinical integration of dynamic biomarker assessment requires further validation.
- A nuanced, context-dependent approach to biomarker interpretation is supported for PCI populations.
Abstract:
Cardiac biomarkers are widely used for risk stratification in patients undergoing percutaneous coronary intervention (PCI), yet their optimal mode of assessment remains uncertain. This systematic review evaluates the prognostic significance of serial, delta, and peak periprocedural cardiac biomarker measurements compared with single baseline measurements. A comprehensive literature search of PubMed/MEDLINE, Scopus, and Web of Science identified nine cohort studies encompassing diverse PCI settings, including elective, primary, and chronic total occlusion interventions. Biomarkers assessed included high-sensitivity and conventional troponin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and creatine kinase-myocardial band (CK-MB), with varying measurement strategies such as baseline, peak, serial, and delta assessments. The findings demonstrate that baseline troponin levels consistently predict outcomes, whereas post-procedural elevations show variable and threshold-dependent prognostic value. In contrast, serial assessment of NT-proBNP appears to enhance prognostic discrimination and reflects underlying pathophysiologic processes such as ischemic burden and reperfusion dynamics. Considerable heterogeneity was observed in biomarker timing, thresholds, and outcome definitions, precluding quantitative synthesis. Overall, the evidence suggests that dynamic biomarker assessment, particularly for natriuretic peptides, may offer incremental value over static measurements, although its clinical integration requires further validation. These findings support a more nuanced, context-dependent approach to biomarker interpretation in PCI populations.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies